Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for Diffuse Large B-cell Lymphoma
View/ Open
File version
Accepted Manuscript (AM)
Author(s)
Keane, Colm
Nourse, Jamie P.
Crooks, Pauline
Nguyen-Van, Do
Mutsando, Howard
Mollee, Peter
Lea, Rodney
Gandhi, Maher K.
Griffith University Author(s)
Year published
2012
Metadata
Show full item recordAbstract
Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A-V158F polymorphisms in Diffuse Large B-cell Lymphoma (DLBCL) treated with CHOP-R. The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy Caucasian controls with regards to FCGR3A-V158F and C1qA-A276G ...
View more >Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A-V158F polymorphisms in Diffuse Large B-cell Lymphoma (DLBCL) treated with CHOP-R. The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy Caucasian controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms . LON incidence and event free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. Results The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared to V/F (p=0.028) and F/F genotypes (p=0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared to 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. Conclusions Polymorphic analysis may be a predictive tool to identify those at high-risk of LON. Prospective studies are required to definitively establish if LON or FCGR3A-158V/V genotype influences outcome.
View less >
View more >Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A-V158F polymorphisms in Diffuse Large B-cell Lymphoma (DLBCL) treated with CHOP-R. The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy Caucasian controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms . LON incidence and event free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. Results The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared to V/F (p=0.028) and F/F genotypes (p=0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared to 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. Conclusions Polymorphic analysis may be a predictive tool to identify those at high-risk of LON. Prospective studies are required to definitively establish if LON or FCGR3A-158V/V genotype influences outcome.
View less >
Journal Title
Internal Medicine Journal
Volume
42
Issue
10
Copyright Statement
© 2012 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma, Internal Medicine Journal, Volume 42, Issue 10, Pages 1113–1119, which has been published in final form at 10.1111/j.1445-5994.2011.02587.x. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
Subject
Immunogenetics (incl. Genetic Immunology)
Cardiorespiratory Medicine and Haematology
Clinical Sciences
Public Health and Health Services